Despite the quality of our first version of EGF/rGel which suffered from impurities and significantly reduced gelonin activity as compared to unmodified gelonin, EGF/rGel-PCI was shown highly tumor specific and potent in two xenograft models [43]. The gene discussed is EGF; the disease is neoplasm.